Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
NewsSNMMI Newsline

Updates to Appropriate Use Criteria for PSMA PET

Thomas A. Hope and Hossein Jadvar
Journal of Nuclear Medicine May 2022, 63 (5) 14N;
Thomas A. Hope
University of California, San Francisco, CA; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hossein Jadvar
University of Southern California, Los Angeles, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

As an indication of how quickly the field of nuclear medicine is advancing, the Appropriate Use Criteria (AUC) for Prostate-Specific Membrane Antigen (PSMA) PET document has been updated (1). This is due to the recent U.S. Food and Drug Administration (FDA) approval of 177Lu-PSMA-617 (Pluvicto, 177Lu-vipivotide tetraxetan; Novartis [Basel, Switzerland]/Advanced Accelerator Applications USA, Inc. [Millburn, NJ]) radiopharmaceutical therapy (RPT). Previously the AUC had scored the indication for a posttreatment prostate-specific antigen (PSA) rise in the metastatic castration-resistant prostate cancer (mCRPC) setting as “may be appropriate.” This was because no available PSMA-targeted therapies would benefit from imaging using PSMA PET. With the approval of PSMA RPT, the PSMA PET AUC Working Group has split this indication into 2 distinct indications (see supplemental materials, available at http://ow.ly/ABfv30sh3uO). The first is “Posttreatment PSA rise in the mCRPC setting in a patient not being considered for PSMA-targeted radiopharmaceutical therapy,” which was again scored as “may be appropriate,” because the clinical value of improved tumor localization in grossly metastatic disease is not clear in patients who are not being considered as candidates for PSMA RPT. The second indication is “Evaluation of eligibility for patients being considered for PSMA-targeted radiopharmaceutical therapy,” which was scored as “appropriate” given the availability of a PSMA-targeted therapy.

An important point is that the AUC Working Group agreed that both 18F-DCFPyL (Pylarify, 18F-piflufolastat; Lantheus [Billerica, MA]) and 68Ga-PSMA-11 (Illuccix and Locametz, 68Ga-gozetotide; Telix Pharmaceuticals Ltd. [Melbourne, Australia], and Novartis/AAA, respectively) should be considered equivalent for selection of patients for treatment with 177Lu-PSMA-617. In the prescribing information for 177Lu-PSMA-617, the FDA recommended selection of “patients for treatment using Locametz or an approved PSMA-11 imaging agent based on PSMA expression in tumors.” However, given the near equivalency of 68Ga-PSMA-11 and 18F-DCFPyL, either of these radiotracers can be used for patient selection.

Another consideration for patient selection is what cutoff should make a patient eligible. Two randomized trials have evaluated 177Lu-PSMA-617 therapy: the VISION and TheraP trials. Optimal PSMA PET criteria for patient selection are not yet well established. In the VISION trial, eligibility required uptake in disease greater than that in the liver, and no measurable disease with uptake less than that in the liver (2). Eligibility in the TheraP study required an SUV ≥20 at 1 site of disease, an SUV ≥10 at measurable soft tissue sites, and no 18F-FDG–positive PSMA-negative sites of disease (3). It should be noted that, in general, the higher the uptake on PSMA PET, the better patients respond to treatment (4,5). PSMA PET is not only a prognostic biomarker but was shown to be predictive in the TheraP trial, with patients who had an SUVmean ≥10 having a higher likelihood of PSA response compared to chemotherapy (cabazitaxel) (6). Although the decision in the VISION trial was binary, uptake may be used to help weigh various treatment options. The debate as to whether 18F-FDG PET/CT should also be used to screen patients prior to PSMA RPT is outside of the scope of the PSMA PET AUC, although 18F-FDG PET may provide additional value in identifying 18F-FDG–positive/PSMA-negative sites of disease (3).

PSMA PET plays a significant role in the appropriate selection of patients for PSMA RPT. With the approval and availability of 2 PSMA PET agents, this imaging study should be widely available. Overall, these 2 imaging agents are considered equivalent for patient selection.

  • © 2022 by the Society of Nuclear Medicine and Molecular Imaging.

REFERENCES

  1. 1.↵
    1. Jadvar H,
    2. Calais J,
    3. Fanti S,
    4. et al
    . Appropriate use criteria for prostate-specific membrane antigen PET imaging. J Nucl Med. 2022;63:59–68.
    OpenUrlFREE Full Text
  2. 2.↵
    1. Kuo PH,
    2. Benson T,
    3. Messmann R,
    4. Groaning M
    . Why we did what we did: PSMA-PET/CT selection criteria for the VISION trial. J Nucl Med. January 2022:jnumed.121.263638.
  3. 3.↵
    1. Hofman MS,
    2. Goh JC,
    3. Tan TH,
    4. et al
    . [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): A randomised, open-label, phase 2 trial. Lancet. 2021;351:1502–1506.
    OpenUrl
  4. 4.↵
    1. Gafita A,
    2. Calais J,
    3. Grogan TR,
    4. et al
    . Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: An international, multicentre, retrospective study. Lancet Oncol. 2021;22:1115–1125.
    OpenUrl
  5. 5.↵
    1. Seifert R,
    2. Seitzer K,
    3. Herrmann K,
    4. et al
    . Analysis of PSMA expression and outcome in patients with advanced prostate cancer receiving 177Lu-PSMA-617 radioligand therapy. Theranostics. 2020;10:7812–7820.
    OpenUrl
  6. 6.↵
    1. Buteau JP,
    2. Martin AJ,
    3. Emmett L,
    4. et al
    . PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603) [abstract]. J Clin Oncol. 2022;40(6; suppl):10-10.
    OpenUrl
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 63, Issue 5
May 1, 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Updates to Appropriate Use Criteria for PSMA PET
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Updates to Appropriate Use Criteria for PSMA PET
Thomas A. Hope, Hossein Jadvar
Journal of Nuclear Medicine May 2022, 63 (5) 14N;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Updates to Appropriate Use Criteria for PSMA PET
Thomas A. Hope, Hossein Jadvar
Journal of Nuclear Medicine May 2022, 63 (5) 14N;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • REFERENCES
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • SNMMI Newsline
  • FDA Approves Pluvicto/Locametz for Metastatic Castration-Resistant Prostate Cancer
Show more SNMMI Newsline

Similar Articles

SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire